Clinical Trial News and Research

RSS

CEL-SCI closes previously announced registered direct offering

CEL-SCI Corporation announced today that it has closed its previously announced registered direct offering for the sale of (i) 13,333,334 shares of its common stock at a price per share of $0.30 and (ii) warrants to purchase up to 12,000,000 shares of CEL-SCI Corporation's common stock at a purchase price of $0.40. The warrants may be exercised at any time prior to October 6, 2014.

7 Oct 2011

Increasing levels of 'good' cholesterol reduces risk for heart attack and stroke among diabetics

Increasing levels of high-density lipoproteins, better known as HDL or "good" cholesterol, reduced the risk for heart attack and stroke among patients with diabetes. That's according to a new study appearing online today in The American Journal of Cardiology.

7 Oct 2011

Cannabidiol could prevent onset of pain associated with chemotherapy drugs

A chemical component of the marijuana plant could prevent the onset of pain associated with drugs used in chemo therapy, particularly in breast cancer patients, according to researchers at Temple University's School of Pharmacy.

7 Oct 2011

Tips on how to prevent unnecessary medication/supplement mishaps

Navigating the supplement and medication maze can get confusing especially when you have multiple prescriptions. It is important to organize yourself with your medications and supplements to prevent unnecessary mishaps.

7 Oct 2011

Scientists discover rare genetic alteration responsible for hypoglycaemia

Cambridge scientists have identified the cause of a rare, life-threatening form of hypoglycaemia. Their findings, which have the potential to lead to pharmaceutical treatments for the disorder, were published today, 07 October, in the journal Science.

7 Oct 2011

Teriflunomide drug reduces relapse rate of people with MS

A new oral drug has been shown in a large international clinical trial to significantly reduce the relapse rate of people with multiple sclerosis and to slow the progression of the disease.

7 Oct 2011

Three Penn labs receive NIH grant to speed translation of medical research into patient care

Three labs from the University of Pennsylvania have received $12.5 million from the National Institutes of Health (NIH) as part of its $143.8 million national grant program to challenge the scientific status quo with innovative ideas that have the potential to speed the translation of medical research into improved health for the American public.

4 Oct 2011

Orexigen presents data from Contrave trial at 29th Annual Scientific Meeting of The Obesity Society

Orexigen Therapeutics, Inc., today announced that Contrave (naltrexone SR/bupropion SR) data will be presented in one oral and multiple poster presentations at the 29th Annual Scientific Meeting of The Obesity Society on October 3, 2011 in Orlando, FL.

4 Oct 2011

MR-guided focused ultrasound may effectively control essential tremor

In a presentation at the Congress of Neurological Surgeons today, University of Virginia neurosurgeon W. Jeffrey Elias, MD reported that preliminary results of a pilot clinical trial indicate that MR-guided focused ultrasound has the potential to safely and effectively control essential tremor (ET), a common neurological condition that affects 10 million Americans.

4 Oct 2011

GeoVax completes enrollment for HIV/AIDS vaccine Phase 2a clinical trial

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today the completion of enrollment for a Phase 2a clinical trial testing its HIV/AIDS vaccine.

3 Oct 2011

HeartWare announces updated clinical data from BTT study, ADVANCE and CAP

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced updated clinical data from its bridge to heart transplantation (BTT) study, ADVANCE, and the Continued Access Protocol.

3 Oct 2011

Marken introduces new global brand and advertising campaign

Marken, a global leader in supporting clinical research logistics, announced the launch of a new global brand and advertising campaign to reflect the unique position that it holds in the pharmaceutical industry.

3 Oct 2011

Planned clinical trial of Adeona's zinc-based therapy for ALS patients to be featured at ALS Summit

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that its planned clinical trial of the Company's proprietary zinc-based therapy for patients suffering from amyotrophic lateral sclerosis, also known as Lou Gehrig's Disease, will be featured during the Hot Topics session at the 2011 California ALS Research Summit on Saturday, October 1, 2011.

1 Oct 2011

Safeway introduces chain-wide breast cancer fundraising initiative

Safeway Inc. today launched its annual October chain-wide breast cancer fundraising initiative. The company has raised more than $94 million for the cause since 2001.

1 Oct 2011

Wireless Vital Signs Monitor for trauma victims enters clinical trial phase

A collaboration among a medical device innovator, the U.S. Army Institute of Surgical Research (ISR), the nonprofit National Trauma Institute and the State of Texas enters its final phase as the FDA-approved Wireless Vital Signs Monitor (WVSM) begins clinical trials this month in the Memorial Hermann Medical Center emergency department and on Houston Life Flight.

1 Oct 2011

Pfizer releases Phase III study results comparing VFEND-ERAXIS combination to VFEND for IA

Pfizer Inc. today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis, a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems.

1 Oct 2011

CoreValve prosthesis shows promise against severe aortic stenosis

Among individuals 65 years and older, as many as 30 percent have aortic valve sclerosis or stenosis and as a result of their deteriorating health, cannot enjoy a normal lifestyle. "The aortic valve is a gatekeeper," says Marco Costa, MD, of University Hospitals (UH) Case Medical in Cleveland.

From Medtronic 1 Oct 2011

Baxter seeks European marketing authorization for HyQ to treat PI

Baxter International Inc. announced today that it has submitted an application to the European Medicines Agency's Committee for Human Medicinal Products seeking marketing authorization for HyQ. HyQ is Baxter's investigational immunoglobulin (IG) therapy administered subcutaneously and facilitated by recombinant human hyaluronidase, a dispersion and permeation enhancer, for use in patients with primary immunodeficiencies.

From Baxter International Inc. 1 Oct 2011

JenaValve's transapical TAVI system receives CE mark approval to treat aortic valve stenosis

JenaValve Technology GmbH, a German medical device company specializing in the development of transcatheter heart valve implantation systems, announced today that the Company has received CE mark approval for its transapical TAVI system of the second-generation. This system is used to treat severe aortic valve stenosis in elderly high-risk patients, especially in patients for whom conventional open-heart surgery is not an option.

1 Oct 2011

Report on best practices in Phase IV clinical trials

Phase IV clinical research is growing rapidly, meaning expanding budgets for post-marketing research studies. And more of that work is being done by third parties and specialized vendors, according to a new study from Cutting Edge Information.

30 Sep 2011